Nastech To Develop Non-Injectable Dosage Form Of Factor IX To Control Bleeding
Nastech Pharmaceutical to develop an alternative dosage form of Factor IX protein which is currently administered by injection to control and prevent bleeding in patients with hemophilia B.
"We look forward to working with our new global partner to evaluate the feasibility of delivering Factor IX without an injection," stated Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech. "Patients with hemophilia B, a result of deficiency in the Factor IX protein, require a lifetime of frequent injections in order to manage their condition. An alternative to these injections would be welcomed by patients and their caregivers."
Factor IX is a protein produced naturally in the body that helps the blood to form clots. Hemophilia B, also known as Christmas disease, is a condition in which the body does not make enough Factor IX and is treated by injections of the protein. If a person does not have enough Factor IXand becomes injured, the blood will not form clots and they may bleed into and damage muscles and joints.